High-risk acute coronary syndromes: cost-effectiveness of clopidogrel plus aspirin
This article has no abstract so we have provided the first paragraph of the full text.
Combination therapy with clopidogrel and aspirin has been shown to be more effective than aspirin alone in reducing the risk of myocardial infarction, stroke or cardiovascular death in patients with unstable angina. Information is lacking, however, on the relative cost-effectiveness of these two strategies. Schleinitz et al. have addressed this question in their recent cost–utility analysis, using data from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mathematical physics Added dimensions to grain growthNature News and Views (26 Apr 2007)
